NEWS
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
AlloVir has announced a merger with Kalaris Therapeutics in an all-stock transaction. The combined company will focus on developing TH103, a novel anti-VEGF therapy for retinal diseases, invented by Dr. Napoleone Ferrara. After the merger, pre-Merger AlloVir stockholders will own 25.05% and Kalaris stockholders 74.95% of the combined company. The merged entity will have approximately $100 million in cash, providing runway into Q4 2026, and will trade as Kalaris Therapeutics (KLRS) on Nasdaq. TH103 is currently in Phase 1 trials for neovascular age-related macular degeneration, with initial data expected in Q3 2025. The therapy targets the $14 billion global branded anti-VEGF retinal market.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2595Followers
107Following
28KVisitors
Follow